

**Freedom of Information Request****Ref: UHB 17-644**

Date 7 December 2017

[REDACTED]

[REDACTED]

[REDACTED]

Thank you for your request for information under the Freedom of Information Act 2000. The Trust's response is as follows:

After further conversations with the relevant clinical colleagues, we have clarified that the information we were unable to provide is actually the data on how many patients have treatment then switch to palliative care. We can provide the following information in relation to your original request. I hope you find this helpful.

**1. How many of the following patients (excluding clinical trial patients) are currently being managed by your Health Trust:**

As previously discussed, we do not hold information on how many patients have treatment then switch to palliative, however please see table below for 2016/17.

<b>Patient Type</b>	<b>All Non-Small Cell Lung Cancer (NSCLC) patients</b>	<b>Patients with NSCLC Stage IIIB**/IV** (Stage 3b/4)</b>
<b>Total number of patients (treated and not treated)</b>	356	111
<b>Number currently treated with any active anti-cancer drug treatment (excl. surgery/ radiotherapy only)</b>	74	52
<b>Number not treated</b>	23	7

**2. Of the Stage IIIB/IV NSCLC patients, please state the number of patients currently being treated with the following therapies:**

<b>Therapy</b>	<b>Number of Stage IIIB/IV NSCLC patients currently treated</b>
Afatinib (Giotrif)	**
Ceritinib (Zykadia)	**
Crizotinib (Xalkori)	**
Erlotinib (Tarceva)	**
Gefitinib (Iressa)	**
Nintedanib + docetaxel	**
Pemetrexed (Alimta) mono or in combination with carboplatin / cisplatin	12
Gemcitabine mono or in combination with carboplatin / cisplatin	12
Atezolizumab (Tecentriq)	0
Nivolumab (Opdivo)	**
Pembrolizumab (Keytruda)	7
Paclitaxel mono or in combination with carboplatin / cisplatin	0
Doxetaxel mono or in combination with carboplatin / cisplatin	0
Vinorelbine [or other Vinka alkaloid] mono or in combination with carboplatin / Cisplatin	**

Where the figures are fewer than 5, this has been denoted by \*\*. Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. In our view disclosure of these low figures would breach one of the Data Protection Principles set out in Schedule 1 of the Data Protection Act, namely Principle 1. Therefore under Section 40(2) of the Freedom of Information Act 2000, we will not be disclosing this information at this time. Section 40 is the exemption for personal information

This concludes our response. We trust that you find this helpful, but please do not hesitate to contact us directly if we can be of any further assistance.

If, after that, you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to:

Trust Secretary  
University Hospitals Bristol NHS Foundation Trust  
Trust Headquarters  
Marlborough Street  
Bristol  
BS1 3NU

Please remember to quote the reference number above in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF

To view the Freedom of Information Act in full please click [here](#).

Yours sincerely,

██████████  
██████████